Atlas Trials

Phase I Study of Repotrectinib and Osimertinib in NSCLC Patients

Clinical trial NCT04772235 · UNKNOWN

Trial details

NCT number
NCT04772235
Sponsor
Instituto Oncológico Dr Rosell
Status
UNKNOWN
Phase
Phase 1
Study type
INTERVENTIONAL
Nsclc
Start date
2022-02-11
Primary completion
2026-04-01
Enrollment
32

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.